Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01301
|
|||||
| Drug Name |
Deoxycholic acid
|
|||||
| Synonyms |
(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-oic acid; 3,12-Dihydroxycholanic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 5-beta-Deoxycholic acid; 7-Deoxycholic acid; 7alpha-Deoxycholic acid; ATX-101; Choleic acid; Cholerebic; Cholic acid, deoxy-; Cholorebic; DEOXYCHOLIC ACID; Degalol; Deoxy cholic acid; Deoxycholatic acid; Desoxycholic acid; Desoxycholsaeure; Dihydroxycholanoic acid; Droxolan; Pyrochol; Septochol; Sodium deoxycholate; deoxycholate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Fat below the chin [ICD11: 5B80] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C24H40O4
|
|||||
| Canonical SMILES |
CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C
|
|||||
| InChI |
InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
|
|||||
| InChIKey |
KXGVEGMKQFWNSR-LLQZFEROSA-N
|
|||||
| CAS Number |
CAS 83-44-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 392.6 | Topological Polar Surface Area | 77.8 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
4.9
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:28834
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ASBT | Transporter Info | Apical sodium-dependent bile acid transporter | Substrate | [2] | |
| BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
| References | ||||||
| 1 | Deoxycholic acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018 Jan;151:13-23. | |||||
| 3 | Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.